Table 1

Quantification of day of onset, clinical score, and paralysis in EAE experiments

Experiment	Genotype	Mice, n	Day of onset (95% CI)	p	Maximum clinical score(95% CI)	p	Paralysis, %	p
1	lysM-Cre:HIF-1α^fl/fl	17	11.7 (11.0–12.5)	0.77^f	2.71 (2.43–2.98)	0.77^g	23.5	0.73^h
1	HIF-1α^fl/fl	22	11.4 (11.0–12.0)	0.77^f	2.79 (2.54–3.02)	0.77^g	31.8
2	lysM-Cre:VHL^fl/fl	20	7.95 (7.0–9.5)	0.90ⁱ	2.95 (2.32–3.52)	0.90^j	50	0.99^k
2	VHL^fl/fl	15	8.56 (7.0–10.0)	0.90ⁱ	2.82 (2.15–3.47)	0.90^j	46.7
3	GFAP-Cre:HIF-1α^fl/fl	24	11.40 (11.0–12.0)	0.99 ^s	2.81 (2.43–3.17)	0.99 ^t	62.5	0.78 ^u
3	HIF-1α^fl/fl	27	11.29 (11.0–12.0)	0.99 ^s	2.96 (2.64–3.26)	0.99 ^t	55.6
4	GFAP-Cre:lysM-Cre:HIF-1α^fl/fl	16	11.44 (10.5–12.0)	0.65 ^v	2.56 (2.26–2.88)	0.98 ^w	12.5	0.19 ^x
4	HIF-1α^fl/fl	13	11.98 (11.5–12.5)	0.65 ^v	2.57 (2.27–2.86)	0.98 ^w	38.5

Experiment 1: EAE induction in lysM-Cre:HIF-1α^fl/fl versus control mice HIF-1α^fl/fl. Experiment 2: EAE induction in lysMCre:VHL^fl/fl versus control mice VHL^fl/fl . Experiment 3: EAE induction in GFAP-Cre:HIF-1α^fl/fl versus control mice HIF-1α^fl/fl . Experiment 4: EAE induction in GFAP-Cre:lysM-Cre:HIF-1α^fl/fl versus control mice HIF-1α^fl/fl . Day of onset defined as the first day that the score is ≥0.5. A linear mixed-effects model was used to estimate means and 95% confidence interval (CI) for both day of onset and maximum clinical score for each genotype group. A Fisher’s exact test was used to determine whether there is a significant relationship between genotype and mice that achieve score 3 or higher during the experiment (percentage paralysis). Superscript letters refer to the statistical results in Figures 3A, 3B, 5A and 5B. Results, and Table 2.